FindTrial
Sign In

Pharmacokinetic properties of the zinc agent polaprezinc in subjects with zinc deficiency

Z-103 clinical pharmacological study--the effect of a single administration of Z-103 to subjects with zinc deficiency--

Status
Unknown
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080221593
Enrollment
6
Registered
2011-09-22
Start date
2011-09-22
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

male subjects

Interventions

investigational material(s) Generic name etc : Z-103 INN of investigational material : polaprezinc Therapeutic category code : 232 Agents for peptic ulcer Dosage and Administration for Investigational

Sponsors

Zeria Pharmaceutical Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: - subjects with low serum zinc concentrations (<70 microgram /dL) - subjects with a body mass indexes (BMI) ranging from 18.5 to 25.0

Exclusion criteria

Exclusion criteria: - Subjects allergic to zinc, with abnormal hepatic, renal, or cardiac function, drug or alcohol dependence, tobacco use, or acute or chronic disorders that might interfere with drug absorption - Subjects who received any medication within the 7 days prior to the date of drug administration

Design outcomes

Primary

MeasureTime frame
plasma zinc concentration N/A—

Secondary

MeasureTime frame
N/A N/A—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026